Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)

- NDA submitted for the treatment of central diabetes insipidus -
- Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch –

DEER PARK, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ET-600, Eton’s proprietary, patented oral solution of desmopressin under development for the treatment of central diabetes insipidus. The Company expects the application to be assigned a 10-month FDA review, allowing for potential approval and launch in the first quarter of 2026.

Read more at globenewswire.com